WeightWatchers eyes menopause care as it emerges from financial overhaul and returns to Nasdaq
Company appoints Dr Kim Boyd as Chief Medical Officer and announces tailored programme for midlife women
WeightWatchers has emerged from bankruptcy, unveiling an ambitious pivot into women’s health with a new focus on menopause care and a refreshed leadership team.
The global weight management brand – long known for its community-based, behavioural approach to weight loss – is moving to integrate clinical care and personalised support for women in midlife. At the heart of this shift is the appointment of Dr Kim Boyd, a seasoned physician with a background in metabolic and women’s health, who joins the company as its new Chief Medical Officer.
The company has completed a strategic reorganization and relisted as a public company on Nasdaq.
“This is a pivotal moment for WeightWatchers,” said CEO Tara Comonte.
“With renewed financial strength, an expanded leadership team, and the addition of Dr Kim Boyd to lead clinical strategy and program innovation, we’re accelerating our transformation. From broadening our reach into women’s health to strengthening our holistic care model, we’re bringing together medical expertise, behavioral science, and trusted community support to meet the evolving needs of our members.”
Integrated programme for perimenopause, menopause and postmenopause
The company plans to launch its first integrated programme for perimenopause, menopause, and postmenopause later this year. It will combine medical support – including GLP-1 medications – with tailored nutritional guidance, coaching, and lifestyle interventions, in a move WeightWatchers says is designed to fill a longstanding gap in women’s healthcare.
WeightWatchers’ expanded offering comes amid growing interest in menopause support, a field often criticised for being underserved by both healthcare providers and mainstream wellness platforms. The company says its holistic approach has already demonstrated "meaningful, sustained weight loss" among women at this life stage, significantly outperforming self-directed methods.
Dr Boyd, whose previous roles include stints at One Medical, Calibrate, and Galileo, brings experience at the intersection of tech-driven health and clinical care. She said:
“WeightWatchers’ mission has never been more important, with nearly three-quarters of Americans and more than two billion people around the world affected by obesity or excess weight.
“We know just how profoundly weight impacts long-term health. For more than six decades, WeightWatchers has supported tens of millions of people on their weight loss journeys. We’re expanding that legacy by combining the best tools of modern medicine, like GLP-1s, with science-backed lifestyle change and the power of community to deliver better outcomes.”
Expanded leadership team
The organisation also announced a series of high-profile leadership hires as part of its post-restructuring strategy. Uta Knablein joins as Chief Product Officer, bringing product development experience from companies including iHeartMedia and JPMorgan Chase. Mike Amsel, formerly with SiriusXM and Pandora, becomes Chief Marketing Officer, while Samhita Mukhopadhyay, a prominent editorial voice in women’s wellness, will head content strategy.
WeightWatchers has also promoted Jacquie Cooke to Chief Legal & Administrative Officer, Jon Volkmann to Chief Operations Officer, and named Tyler Holden as Head of Consumer Research & Insights.
The leadership refresh is supported by a new Board of Directors, featuring industry veterans such as Mike Mason, former President of Eli Lilly’s Diabetes and Obesity division and a key figure in the rise of GLP-1 weight loss drugs.
“I’m excited to join WeightWatchers at such a pivotal moment in the evolution of obesity care,” said Mason.
“As medical treatments like GLP-1s become more widely used, the need for trusted, comprehensive care models that combine medication with lasting lifestyle change has never been greater. WeightWatchers brings unmatched clinical credibility, behavioral expertise, and member trust to this space, and I’m proud to support the team as they lead the industry forward with integrity and innovation.”
The company says the new board and executive team will guide its strategy as it seeks to redefine care for weight and health, particularly for women in midlife – a demographic historically marginalised in health and wellness innovation.
WeightWatchers’ reorganisation, which included a successful relisting under ticker WW, marks a significant reset for the 62-year-old brand. It now aims to move beyond its diet programme roots and into a broader healthcare role, targeting both clinical outcomes and quality of life – especially for women navigating menopause.